Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
Providing research access across a diverse network of 70+ NEALS sites
Common Protocol and Shared Infrastructure Allow for Operational and Scientific Efficiencies

- 1 Protocol (Phase 2/3)
- 1 single IRB
- Central Governance
- 7 Regimens
- 70+ Enrolling Sites
- ~1300 Participants

Regimen: Active Study Drug + Matching Placebo
Enrollment Update: Regimen F and Regimen G

- 471 Participants consented to Master Protocol since RGF and RGG initiated
- 395 Participants assigned to RGF or RGG
- 346 Participants randomized within RGF or RGG

Thank You for your partnership in ALS research (as of 11/30/23)
The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug.

**Primary Endpoint (Placebo-Controlled Period)**
Change from baseline through week 24 in disease severity as measured by the ALSFRS-R total score and survival

**Safety, Secondary, and Exploratory Endpoints**
(respiratory function, muscle strength, survival, biomarkers + regimen-specific endpoints)
The HEALEY ALS Platform Trial is a perpetual trial to provide decisive answers and direction with efficient execution.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Treatment</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regimen A</td>
<td>Zilucoplan by UCB</td>
<td>Summer 2020</td>
</tr>
<tr>
<td>Regimen B</td>
<td>Verdiperstat by Biohaven</td>
<td>2021</td>
</tr>
<tr>
<td>Regimen C</td>
<td>CNM-Au8 by Clene</td>
<td>2022</td>
</tr>
<tr>
<td>Regimen D</td>
<td>Pridopidine by Prilenia</td>
<td>2023</td>
</tr>
<tr>
<td>Regimen E</td>
<td>Trehalose by Seelos</td>
<td>Graduated to Phase 3 Trial</td>
</tr>
<tr>
<td>Regimen F</td>
<td>ABBV-CLS-7262 by Calico &amp; AbbVie</td>
<td>Graduated to Phase 3 Trial</td>
</tr>
<tr>
<td>Regimen G</td>
<td>DNL343 by Denali</td>
<td></td>
</tr>
</tbody>
</table>
Each regimen is compared to the shared placebo dataset, which keeps growing as new regimens are added.

**Participant Flow**

- Enroll in HEALEY ALS Platform Trial
- Randomization

**KEY ELIGIBILITY CRITERIA**

- Sporadic or familial ALS (possible, probable, lab-supported probable, or definite by revised EEC)
- Time since weakness onset ≤ 3 years
- Slow vital capacity ≥ 50% of predicted
- Able to swallow
- Either not take or be on stable dose of riluzole for ≥ 30 days
- Either not take or have completed at least one cycle of edaravone
- Either not take or have started Relyvrio/Albrioza ≥ 30 days prior to screening
The platform trial is a unique opportunity to move ALS biomarkers and new outcome measures forward

**DNA** – whole genome sequencing

**Neurofilaments** – for all regimens + regimen-specific biomarkers based on MOA

**Home Spirometry** – critical during the pandemic

**Speech Analysis** – emerging digital biomarker

Additional biomarkers/outcome measures considered for upcoming and future regimens (e.g., new patient-reported outcomes - ROADS; PBMCs for stem cell generation)
This trial is dedicated to all people living with ALS, their families, and friends. Your partnership in research is what keeps us filled with passion, dedication, and the commitment to develop new treatments for ALS.

This breakthrough trial would not be possible without your participation.

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality.

Thank You
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: https://bit.ly/3o2Ds3m
ALS Link sign-up: https://bit.ly/3r6Nd2L

Upcoming Webinars:
No webinar on December 7th - Cancelled for MND Conference
December 14th - EAP Discussion with Dr. James Berry of Mass General Hospital
No webinar on December 21st or 28th - Happy Holidays!
January 4th - First weekly Q&A webinar of 2024!